Stage report
Clinical Landscape Agent
Who gets the disease and how is it diagnosed?
Verified from a retrieved source
Inferred from several sources
Original analytical construct
Recent update
General knowledge
Not verified
Source = where it came from
Stage 1 · Clinical Landscape Agent
Disease & Diagnostic Foundation
Core question: Who gets the disease and how is it diagnosed?
Framework steps included
Step 1 (Disease definition and natural history), Step 2 (Epidemiology, incidence, prevalence, mortality), Subtype and molecular/cytogenetic classification, Diagnostic criteria and confirmatory workup, Risk stratification and the patient characteristics that drive cohort segmentation and treatment eligibility (age, comorbidity, performance status, organ function)
- Step 2A — Diagnostic criteria and confirmatory-workup research
- Step 2B — Align diagnostic criteria with disease taxonomy, subtypes, stages and population
What happens in this stage
This stage establishes the foundational disease definition, epidemiology, subtype framework, diagnostic context, and cohort-segmenting clinical variables for acute lymphoblastic leukemia (ALL) in the United States through 2026. The supplied evidence supports characterization of ALL as a rare lymphoid malignancy affecting marrow, blood, and potentially extranodal tissues, with important distinctions by age group, lineage subtype, and Philadelphia chromosome status. The stage also identifies which diagnostic and biologic elements are directly evidenced versus incompletely described in the supplied materials for claims-based cohort construction.
Expected output
- Epidemiology snapshot table (Metric | Value | Stage or subtype | Source)
- Subtype / biology breakdown table (Subtype | Approximate share | Notes)
- Diagnostic criteria summary (classification, immunophenotype, cytogenetics, molecular, staging)
- Diagnostic workup table
- Key clinical variables and cohort-defining forks (age, comorbidity, performance status, organ function)
- Key takeaways
Synthesis
Acute lymphoblastic leukemia (ALL) is defined as "a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation," and the disease "primarily affects the bone marrow and peripheral blood" although "the abnormal cells can infiltrate any organ or tissue." Patients may present with "lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage" or may remain asymptomatic. U.S. epidemiology sources state that acute lymphocytic leukemia is "most common in children, adolescents, and young adults" and "most frequently diagnosed among people aged <20," with peak incidence reported between 2 and 5 years of age. SEER estimates for the United States include "Estimated New Cases in 2026: 6,250," "Estimated Deaths in 2026: 1,600," a "5-Year Relative Survival: 73.2% (2016–2022)," and "an estimated 126,118 people living with acute lymphocytic leukemia in the United States" in 2023. Immunophenotypic lineage categories identified in the supplied documents include B-cell ALL and T-cell ALL, with B-ALL associated with "pan B-cell markers (CD19,CD22 and cytoplasmic CD79a)" and T-ALL associated with "cytoplasmic CD3 and CD5." Philadelphia chromosome–positive ALL is specifically identified as a clinically important subtype because "Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL." Adolescents and young adults are described as "a unique population" in whom "Treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting." The supplied evidence supports age group, lineage subtype, relapse status, and Philadelphia chromosome status as clinically relevant cohort-defining forks for claims-based analyses, but detailed formal diagnostic criteria, MRD definitions, and comprehensive cytogenetic classification schemas were not provided in the supplied materials.
Questions and answers
Every question in this stage with the answer established from its sources. This is the record the synthesis and tables above are built from.
What is the disease definition and natural history of acute lymphoblastic leukemia?
The supplied documents define acute lymphoblastic leukemia (ALL) as "A group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation" and note synonymous terminology including "ALL, Acute lymphoblastic leukemia/lymphoma, Acute lymphocytic leukemia, Precursor lymphoid neoplasm." The documents do not provide WHO or ICC disease classification schemas, and they do not explicitly define B-cell versus T-cell lineage classifications. Clinical presentation and natural history information relevant to cohort construction includes that patients "may present with symptoms, frequently including lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage or they may remain asymptomatic," and that disease can involve marrow, blood, and extranodal tissues because "the abnormal cells can infiltrate any organ or tissue." The documents also describe relapse patterns and age-related treatment differences: adult ALL induction regimens achieve "complete response rates that range from 60% to 90%" but "Responses were short lived, with most of these patients experiencing disease relapse," while adolescents and young adults are described as "a unique population" in whom "Treatment regimens can vary significantly depending on whether they receive care in a pediatric or in an adult setting" and who have "distinctive care needs, social risk factors, and disease behavior compared with other age groups." The supplied document addresses lineage classifications and some relapse/natural history patterns for acute lymphoblastic leukemia (ALL), particularly in adolescents and young adults (AYAs) with relapsed/refractory disease. It specifically distinguishes “B-cell acute lymphoblastic leukemia (B-ALL)” and “T-cell ALL,” and describes relapsed/refractory ALL as involving “greater treatment resistance” and “higher rates of toxicity.” The document also references relapse states including “CNS relapse” and patients who “achieve a second (or greater) remission (CR2).” However, the document does not provide WHO/ICC disease definitions, comprehensive disease presentation patterns, or detailed pediatric-versus-adult epidemiology and natural history needed for claims-based line-of-therapy cohort construction. The supplied document identifies acute lymphocytic leukemia (ALL) epidemiology and age-related disease patterns in the United States through 2026, but it does not provide WHO/ICC disease definitions, lineage classifications such as B-cell versus T-cell ALL, or detailed relapse/progression natural history relevant to claims-based line-of-therapy construction. The document states that "Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age" and that "Acute lymphocytic leukemia is most frequently diagnosed among people aged <20," which supports pediatric and young adult predominance. It also reports U.S. burden estimates including "Estimated New Cases in 2026: 6,250" and "Estimated Deaths in 2026: 1,600." The supplied document only addresses a limited aspect of pediatric acute lymphoblastic leukemia management and does not provide WHO/ICC disease definitions, lineage classifications, relapse patterns, progression course, or pediatric-versus-adult epidemiology relevant to claims-based line-of-therapy cohort construction. The document states that "Pediatric maintenance therapy for acute lymphoblastic leukemia requires prolonged daily administration of 6-mercaptopurine (6-MP), a drug characterized by a narrow therapeutic index and substantial interindividual variability." It also describes that this therapy involves "prolonged daily administration" during pediatric maintenance treatment.
What is the incidence, prevalence, survival and mortality of ALL in the United States, stratified by age group and subtype (B-ALL, T-ALL, Ph-positive)?
The supplied documents provide limited U.S. epidemiology and survival information for acute lymphoblastic leukemia (ALL), primarily for pediatric ALL incidence and adult leukemia survival trends, but they do not provide comprehensive U.S. estimates through 2026, prevalence estimates, mortality rates, or subtype-specific epidemiology for B-ALL, T-ALL, and Philadelphia chromosome-positive ALL. One CDC report states that “Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children and adolescents in the United States” and reported that “Overall incidence of pediatric ALL during 2001–2014 was 34.0 cases per 1 million persons and among all racial/ethnic groups was highest among Hispanics (42.9 per 1 million).” The same report noted that “Both overall and among Hispanics, pediatric ALL incidence increased during 2001–2008 and remained stable during 2008–2014.” A separate population-based survival study stated that “The lifetime risk of developing leukemia in the United States is 1.5%” and that “Five-year net survival was estimated using data for 370,994 patients from 43 registries in 37 states and in 6 metropolitan areas, covering approximately 81% of the adult (15–99 years) US population,” but the excerpt provided does not include ALL-specific survival values. In the United States, SEER reports that “The rate of new cases of acute lymphocytic leukemia was 1.9 per 100,000 men and women per year” and “The death rate was 0.4 per 100,000 men and women per year,” with “Estimated New Cases in 2026: 6,250” and “Estimated Deaths in 2026: 1,600.” SEER also states that “In 2023, there were an estimated 126,118 people living with acute lymphocytic leukemia in the United States” and that “5-YearRelative Survival: 73.2% (2016–2022).” Age-related epidemiology is described as follows: “Acute lymphocytic leukemia is most common in children, adolescents, and young adults, or those 15 to 39 years of age,” “Acute lymphocytic leukemia is most frequently diagnosed among people aged <20,” and Orphanet reports that “The peak incidence occurs between 2 and 5 years of age.” The supplied documents do not provide U.S. incidence, prevalence, survival, mortality, or subtype distribution estimates specifically for B-ALL, T-ALL, or Philadelphia chromosome-positive ALL. The supplied document provides childhood lymphoid leukaemia 5-year net survival estimates for multiple countries in 2021, but it does not provide United States-specific incidence, prevalence, mortality, subtype distribution, or subtype-specific epidemiology for acute lymphoblastic leukemia (ALL), including B-ALL, T-ALL, or Philadelphia chromosome-positive ALL. The document reports that childhood cancer survival for lymphoid leukaemia reached high levels in several countries, including “GBR 2021 AGEGROUP_YEARSLESS20 = 92.5 [90.2-94.3]”, “DEU 2021 AGEGROUP_YEARSLESS20 = 90.6 [87.1-93.2]”, and “DNK 2021 AGEGROUP_YEARSLESS20 = 92.2 [88.3-94.8]”. No data through 2026 for the United States are included. The supplied document does not provide numerical estimates for incidence, prevalence, survival, or mortality of acute lymphoblastic leukemia (ALL) in the United States through 2026, nor does it provide subtype-specific epidemiology for B-ALL, T-ALL, or Philadelphia chromosome-positive ALL. The document does identify adolescents and young adults (AYAs) as a distinct population with differing disease behavior and treatment settings, and it references major ALL subtypes including B-cell and T-cell ALL. It also states that pediatric-inspired frontline regimens are recommended for AYAs with B-ALL or T-ALL.
What are the clinically important immunophenotypic and molecular subtypes of ALL?
The supplied documents identify acute lymphoblastic leukemia (ALL) broadly as “a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation,” but they do not provide a comprehensive listing of immunophenotypic, cytogenetic, molecular, Philadelphia chromosome, prognostic, or biomarker-defined ALL subtypes for claims-based cohort definition. The relapsed/refractory ASH guideline specifically references “ALL subsets (T-cell ALL)” and discusses “immunotherapy” and “targeted therapies,” while the frontline guideline states that “higher-risk subsets” and “targeted agents” are clinically relevant in management decisions. No explicit cytogenetic abnormalities, molecular alterations, Philadelphia chromosome-positive/negative categories, or named targetable biomarkers are enumerated in the provided documents. The supplied document identifies Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph-positive ALL) as a clinically important molecular/cytogenetic subtype in adult ALL treatment. It states that “inclusion of imatinib into a relatively standard chemotherapy regimen for newly diagnosed adult patients with Ph-positive ALL may provide a significant survival advantage,” and that “Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.” The document also notes prognostic implications for this subtype, stating that “remissions are generally short with conventional ALL chemotherapy clinical trials.” The document does not provide additional immunophenotypic subtypes, broader cytogenetic or molecular alteration categories, prognostic subtype groups, or other targetable biomarkers. The supplied document identifies clinically relevant immunophenotypic subtypes of acute lymphoblastic leukemia (ALL), specifically B-cell ALL and T-cell ALL, and describes marker-defined lineage assignment by flow cytometry. B-ALL was characterized by expression of "pan B-cell markers (CD19,CD22 and cytoplasmic CD79a)" with many cases expressing CD10, while T-ALL was characterized by "cytoplasmic CD3 and CD5." The document also notes aberrant myeloid marker expression in some B-ALL cases and describes immunophenotyping as important for "diagnosis, accurate classification, subtyping and treatment programs." However, the document does not provide a comprehensive description of clinically important cytogenetic abnormalities, molecular alterations, Philadelphia chromosome status, prognostic subtype groups, or targetable biomarkers for U.S. ALL patients through 2026. The documents identify clinically important immunophenotypic ALL subtypes including B-cell and T-cell categories. One source states that the WHO system recognizes “Precursor B cell ALL,” “Precursor T cell ALL,” and “Mature B cell ALL (Burkitt type ALL),” while another notes that “the only subtype recognized by the World Health Organization’s International Consensus Classification is early T-cell precursor ALL.” The materials also identify Philadelphia chromosome-related disease biology, including “Philadelphia chromosome-like ALL (Ph-like ALL)” as “a precursor B-cell ALL that results in a change of the chromosomes on the leukemia cells.” Cytogenetic and molecular characterization is described broadly through “genomic subtypes,” “whole transcriptome, exome, or genome sequencing,” “immunophenotyping and cytogenetic testing,” and “specific genomic alterations,” but the supplied documents do not provide a complete enumeration of clinically important cytogenetic abnormalities, molecular alterations, prognostic subtype groups, or targetable biomarkers through 2026.
How is ALL diagnosed and what confirmatory workup is required?
The supplied document identifies acute lymphoblastic leukemia (ALL) as "a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation" and states that it "primarily affects the bone marrow and peripheral blood." It also notes that "the abnormal cells can infiltrate any organ or tissue" and describes common presenting features including "lymphadenopathy, hepatosplenomegaly, bone pain, fever and signs of hemorrhage." However, the documents do not provide diagnostic criteria or confirmatory workup details such as bone marrow evaluation methods, flow cytometry, cytogenetic testing, molecular diagnostics, imaging/CNS assessment, or laboratory testing used for subtype classification, treatment initiation, or claims cohort identification. The supplied document is a frontline management guideline for adolescents and young adults with acute lymphoblastic leukemia and does not describe detailed diagnostic criteria or confirmatory diagnostic workup for establishing ALL diagnosis or subtype classification. The document identifies disease categories relevant to treatment initiation, including “B-cell or T-cell acute lymphoblastic leukemia (B-ALL/T-ALL) or T-cell acute lymphoblastic lymphoma (T-LBL/LLy),” and discusses frontline therapy recommendations and therapeutic drug monitoring for asparaginase management. The document does not provide specific recommendations or criteria regarding bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging, CNS assessment, or laboratory diagnostic workup. The supplied document concerns management recommendations for relapsed/refractory acute lymphoblastic leukemia (ALL) in adolescents and young adults and does not describe the diagnostic criteria or confirmatory workup used to establish ALL diagnosis and subtype classification. The document references disease subsets and central nervous system (CNS)-directed therapy but does not provide details on bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging/CNS assessment methods, or laboratory workup for treatment initiation or claims cohort identification. The supplied document discusses remission induction therapy for adult acute lymphoblastic leukemia (ALL) and mentions treatment considerations for newly diagnosed and Philadelphia chromosome–positive ALL, but it does not describe the diagnostic criteria or confirmatory diagnostic workup used to establish ALL diagnosis or subtype classification. The document does not provide information on bone marrow evaluation, flow cytometry, cytogenetic testing, molecular diagnostics, imaging or CNS assessment, or laboratory workup for treatment initiation or claims cohort identification. The supplied documents indicate that NCCN Guidelines through 2026 address acute lymphoblastic leukemia (ALL) diagnosis and classification with emphasis on subtype classification using immunophenotype and cytogenetic/molecular markers, as well as risk assessment and treatment strategies. However, the documents provided do not contain the detailed diagnostic criteria or confirmatory workup elements requested, such as specific bone marrow evaluation parameters, flow cytometry panels, cytogenetic assays, molecular diagnostics, CNS/imaging assessment, or laboratory workup protocols for treatment initiation or claims cohort identification.
How is ALL risk-stratified at diagnosis, and which patient characteristics drive cohort segmentation and treatment eligibility (age, comorbidity, performance status, organ function)?
The supplied document discusses treatment approaches for newly diagnosed adult acute lymphoblastic leukemia (ALL), including distinctions for Philadelphia chromosome (Ph)-positive disease, but it does not describe formal risk stratification systems, claims-based cohort segmentation methods, age-based eligibility thresholds, performance status criteria, comorbidity burden measures, organ function criteria, or minimal residual disease (MRD) status definitions. The document states that “Most current induction regimens for patients with adult ALL include combination chemotherapy with prednisone, vincristine, and an anthracycline” and that “Imatinib is generally incorporated into the treatment of patients with Ph-positive ALL because of the responses observed in monotherapy trials.” It also notes that “If a suitable donor is available, allogeneic bone marrow transplant should be considered because remissions are generally short with conventional ALL chemotherapy clinical trials.” The supplied documents describe adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) as a distinct population and note that frontline treatment decisions differ between pediatric and adult treatment settings. They also state that allogeneic hematopoietic stem cell transplantation in first remission “may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy,” implying some form of risk stratification and response assessment. However, the documents do not specify the diagnostic risk stratification systems, claims-based cohort segmentation methods, age cutoffs for treatment eligibility, performance status criteria, comorbidity burden measures, organ function requirements, or minimal residual disease (MRD) definitions used in United States patients through 2026. The supplied documents indicate that NCCN guidelines for acute lymphoblastic leukemia (ALL) through 2026 emphasize “classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers” and “risk assessment and stratification for risk-adapted therapy.” The documents also specify that treatment strategies are differentiated for “Philadelphia chromosome (Ph)-positive and Ph ...” disease categories. However, the provided materials do not describe the detailed risk stratification systems, age-based eligibility thresholds, performance status criteria, comorbidity burden measures, organ function requirements, minimal residual disease criteria, or the demographic and clinical cohort segmentation variables used in claims-based line-of-therapy analyses.
Epidemiology snapshot table
| Metric | Value | Stage or subtype | Source |
|---|---|---|---|
| Estimated new cases in 2026 | 6,250 | Acute lymphocytic leukemia overall | National Cancer Institute, Surveillance, Epidemiology, and End Results Program National Cancer Institute, Surveillance, Epidemiology, and End Results Program |
| Estimated deaths in 2026 | 1,600 | Acute lymphocytic leukemia overall | National Cancer Institute, Surveillance, Epidemiology, and End Results Program National Cancer Institute, Surveillance, Epidemiology, and End Results Program |
| Rate of new cases | 1.9 per 100,000 men and women per year | Acute lymphocytic leukemia overall | National Cancer Institute, Surveillance, Epidemiology, and End Results Program National Cancer Institute, Surveillance, Epidemiology, and End Results Program |
| Death rate | 0.4 per 100,000 men and women per year | Acute lymphocytic leukemia overall | National Cancer Institute, Surveillance, Epidemiology, and End Results Program National Cancer Institute, Surveillance, Epidemiology, and End Results Program |
| Estimated prevalence in 2023 | 126,118 people living with acute lymphocytic leukemia in the United States | Acute lymphocytic leukemia overall | National Cancer Institute, Surveillance, Epidemiology, and End Results Program National Cancer Institute, Surveillance, Epidemiology, and End Results Program |
| 5-year relative survival | 73.2% (2016–2022) | Acute lymphocytic leukemia overall | National Cancer Institute, Surveillance, Epidemiology, and End Results Program National Cancer Institute, Surveillance, Epidemiology, and End Results Program |
| Pediatric ALL incidence during 2001–2014 | 34.0 cases per 1 million persons | Pediatric ALL | CDC / NCHS CDC / NCHS |
| Highest pediatric incidence racial/ethnic group | Hispanics: 42.9 per 1 million | Pediatric ALL | CDC / NCHS CDC / NCHS |
| Peak incidence age | Between 2 and 5 years of age | ALL overall | Orphanet Orphanet |
[VERIFIED] The supplied materials do not provide U.S. subtype-specific incidence, prevalence, survival, or mortality estimates for B-ALL, T-ALL, or Philadelphia chromosome-positive ALL.
Subtype / biology breakdown table
| Subtype | Approximate share | Notes |
|---|---|---|
| B-cell acute lymphoblastic leukemia (B-ALL) | 79.3% of acute lymphoblastic leukemia cases in cited study | Characterized by expression of pan B-cell markers "CD19,CD22 and cytoplasmic CD79a"; 90% expressed CD10. WHO |
| T-cell acute lymphoblastic leukemia (T-ALL) | 20.7% of acute lymphoblastic leukemia cases in cited study | Cytoplasmic CD3 and CD5 were identified as sensitive diagnostic markers. WHO |
| Philadelphia chromosome-positive ALL | Numerical share not provided | Adult Ph-positive ALL management incorporates imatinib into therapy because of observed responses. National Cancer Institute |
| Philadelphia chromosome-like ALL (Ph-like ALL) | Numerical share not provided | Identified as "a precursor B-cell ALL that results in a change of the chromosomes on the leukemia cells" in supplied summary text. Established answer synthesis |
| Early T-cell precursor ALL | Numerical share not provided | Described in supplied summary text as "the only subtype recognized by the World Health Organization’s International Consensus Classification." Established answer synthesis |
[VERIFIED] The supplied materials do not provide a comprehensive U.S. subtype distribution schema or complete cytogenetic/molecular classification system through 2026.
Diagnostic workup table
| Workup element | Evidence in supplied materials | Implication for cohort identification |
|---|---|---|
| Clinical presentation assessment | Patients may present with lymphadenopathy, hepatosplenomegaly, bone pain, fever, hemorrhagic signs, or may remain asymptomatic. Orphanet | Symptom burden alone is insufficient for claims-based diagnostic confirmation. Derived from supplied evidence |
| Disease site involvement | Disease primarily affects bone marrow and peripheral blood and may infiltrate any organ or tissue. Orphanet | Claims may contain hematologic and extranodal manifestations. Derived from supplied evidence |
| Immunophenotyping | B-ALL expressed CD19, CD22, cytoplasmic CD79a, and often CD10; T-ALL expressed cytoplasmic CD3 and CD5. WHO | Immunophenotype-supported lineage assignment is clinically relevant for cohort segmentation. Derived from supplied evidence |
| Cytogenetic/molecular subtype evaluation | NCCN guidance referenced classification based on immunophenotype and cytogenetic/molecular markers. Open web | Philadelphia chromosome-positive ALL is specifically distinguished therapeutically. National Cancer Institute |
| Bone marrow blast thresholds | Specific diagnostic criteria not provided in supplied materials | Cannot operationalize from supplied evidence alone. No direct quote provided |
| CNS diagnostic assessment methods | CNS-directed therapy and CNS relapse are referenced in guidelines. American Society of Hematology | Specific lumbar puncture or imaging workup criteria not provided. No direct quote provided |
[VERIFIED] The supplied documents do not provide detailed confirmatory diagnostic algorithms, laboratory thresholds, or standardized workup protocols for ALL diagnosis.
Key clinical variables and cohort-defining forks
| Variable | Observed relevance | Evidence |
|---|---|---|
| Age group | ALL is most common in children, adolescents, and young adults; AYAs are a unique population. | Treatment regimens can vary between pediatric and adult settings. National Cancer Institute, Surveillance, Epidemiology, and End Results Program; American Society of Hematology |
| Lineage subtype | B-ALL and T-ALL are clinically recognized subtypes. | WHO marker profiles distinguish B-cell and T-cell disease. WHO |
| Philadelphia chromosome status | Ph-positive ALL receives distinct treatment incorporation of imatinib. | Imatinib is generally incorporated into treatment of patients with Ph-positive ALL. National Cancer Institute |
| Relapsed/refractory status | Relapsed/refractory disease associated with greater treatment resistance and higher toxicity. | AYAs with relapsed/refractory ALL face greater treatment resistance and higher rates of toxicity. American Society of Hematology |
| Remission status | CR2 and greater remission states are referenced in supplied materials. | The supplied summary references patients achieving second or greater remission (CR2). Established answer synthesis |
| Response/risk category | Higher-risk subsets or suboptimal responders may receive allogeneic hematopoietic stem cell transplantation in first remission. | Allogeneic hematopoietic stem cell transplantation may be indicated for higher-risk subsets or those with suboptimal responses to initial therapy. American Society of Hematology |
| Performance status criteria | No formal thresholds supplied | ECOG/Karnofsky definitions not provided in supplied evidence. No direct quote provided |
| Organ function eligibility criteria | No formal hepatic, renal, or cardiac criteria supplied | Cannot define operational cutoffs from supplied evidence. No direct quote provided |
| MRD-defined risk strata | MRD definitions not supplied | Minimal residual disease criteria absent from supplied evidence. No direct quote provided |
[INFERENCE] Age group, lineage subtype, Philadelphia chromosome status, and relapse/remission state are the clearest cohort-defining variables directly supported by the supplied materials.
Diagnostic criteria summary
The supplied materials define ALL as "a group of rare Non-Hodgkin lymphoma characterized by malignant proliferation of lymphoid cells blocked at an early stage of differentiation." Disease involvement primarily includes bone marrow and peripheral blood, although leukemic cells "can infiltrate any organ or tissue." Immunophenotypic lineage assignment is described through B-cell and T-cell categories, with B-ALL characterized by markers including CD19, CD22, and cytoplasmic CD79a, while T-ALL is associated with cytoplasmic CD3 and CD5. The supplied materials identify Philadelphia chromosome-positive ALL as a clinically important molecular/cytogenetic subtype because imatinib is incorporated into treatment for this subgroup. NCCN guidance referenced in the supplied evidence notes classification using immunophenotype and cytogenetic/molecular markers together with risk assessment and stratification for therapy selection. Specific WHO/ICC blast thresholds, bone marrow diagnostic criteria, molecular assay standards, CNS staging methods, and formal staging systems were not provided in the supplied materials.
Key takeaways
1. ALL is primarily a pediatric and young adult malignancy, with disease most frequently diagnosed among people aged less than 20 years and peak incidence between ages 2 and 5. National Cancer Institute, Surveillance, Epidemiology, and End Results Program; Orphanet
2. U.S. SEER estimates project 6,250 new cases and 1,600 deaths from acute lymphocytic leukemia in 2026, with 5-year relative survival reported at 73.2% for 2016–2022. National Cancer Institute, Surveillance, Epidemiology, and End Results Program
3. B-cell and T-cell ALL are clinically relevant immunophenotypic categories supported by lineage marker data from flow cytometry-related evidence. WHO
4. Philadelphia chromosome-positive ALL is an explicitly distinct treatment subgroup because imatinib is incorporated into therapy for this population. National Cancer Institute
5. Claims-based cohort construction can directly leverage age group, lineage subtype, Philadelphia chromosome status, and relapse/remission state where observable coding or treatment signals exist, but the supplied evidence does not provide validated MRD, performance status, or organ function definitions. Derived from supplied evidence
Claims observability
| Clinical concept | Signal classification | Basis | Limitation |
|---|---|---|---|
| ALL diagnosis | DIRECT SIGNAL | Disease-specific diagnosis context and epidemiology are explicitly described in supplied materials. | No ICD coding schema or validated claims algorithm provided in supplied evidence. |
| Age group segmentation | DIRECT SIGNAL | Pediatric, adolescent/young adult, and adult distinctions are repeatedly described. | Exact operational age cutoffs for all treatment pathways were not provided. |
| B-ALL versus T-ALL subtype | PROXY SIGNAL | Immunophenotypic lineage markers and subtype labels are described. | Claims data may not consistently encode immunophenotype directly. |
| Philadelphia chromosome-positive ALL | PROXY SIGNAL | Imatinib incorporation is specifically linked to Ph-positive ALL. | Cytogenetic test results themselves were not operationalized in supplied evidence. |
| Relapsed/refractory disease | PROXY SIGNAL | Relapse, CNS relapse, and second remission states are referenced in supplied materials. | Standardized relapse definitions or coding algorithms were not supplied. |
| MRD status | NOT OBSERVABLE | No MRD definitions or testing criteria were supplied. | Cannot define observable MRD-based cohorts from supplied evidence alone. |
A proxy signal is observable in claims only through the listed surrogate; it is not a direct field.
Source disagreements identified in this stage
Key takeaways from this stage
- ALL is described as a rare lymphoid malignancy affecting marrow and blood with potential infiltration into any organ or tissue. Orphanet
- The disease burden is concentrated in children, adolescents, and young adults, with diagnoses most frequent in patients younger than 20 years. National Cancer Institute, Surveillance, Epidemiology, and End Results Program
- U.S. SEER estimates include 6,250 projected new cases and 1,600 projected deaths in 2026. National Cancer Institute, Surveillance, Epidemiology, and End Results Program
- B-ALL and T-ALL are clinically important lineage-defined subtypes identified through immunophenotypic markers. WHO
- Philadelphia chromosome-positive ALL is a distinct molecular subgroup with treatment implications involving imatinib incorporation. National Cancer Institute
- The supplied evidence supports cohort segmentation by age, lineage subtype, Philadelphia chromosome status, and relapse/remission status, while detailed MRD and organ-function stratification variables remain insufficiently specified. Derived from supplied evidence
Assumptions made in this stage
- Acute lymphocytic leukemia and acute lymphoblastic leukemia terminology were treated as referring to the same disease construct because the supplied materials used both terms interchangeably.
- Claims-based cohort segmentation discussion was limited to variables explicitly referenced or reasonably inferable from supplied evidence.
- No attempt was made to infer absent WHO/ICC classification details, MRD definitions, or laboratory thresholds beyond the supplied materials.
- References to NCCN classification by immunophenotype and cytogenetic/molecular markers were included despite originating from supplementary open-web material.
Evidence base for this stage: 63 item(s) from 9 source(s); 54 from approved sources, 9 supplementary web. Tiers represented: 1, 2, 3, 5.